Page Title
Drug Development Pipeline
Amikacin Liposome Inhalation Suspension (Arikayce®)
Status
To PatientsTherapeutic Approach
Anti-Infective
Amikacin liposome inhalation suspension (Arikayce®) is an antibiotic to treat chronic lung infections caused by nontuberculous mycobacteria (NTM).
Status
Arikayce® is FDA approved for the treatment of Mycobacterium avium complex (MAC), which belongs to the nontuberculous mycobacteria (NTM) group.
Sponsor
The program was sponsored by Insmed Incorporated and partially funded by the Cystic Fibrosis Foundation. Multiple clinical trials were conducted within the Therapeutics Development Network.
Recent Amikacin Liposome Inhalation Suspension (Arikayce®) Studies

CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More